Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$29.51

-0.11 (-0.37%)

, RHHBY

Roche

$32.31

-0.11 (-0.34%)

13:04
03/07/17
03/07
13:04
03/07/17
13:04

European Pharma raised to Positive from Neutral at Barclays

Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).

AZN

AstraZeneca

$29.51

-0.11 (-0.37%)

RHHBY

Roche

$32.31

-0.11 (-0.34%)

SHPG

Shire

$184.48

-1.82 (-0.98%)

GSK

GlaxoSmithKline

$41.55

-0.27 (-0.65%)

SNY

Sanofi

$43.16

-0.54 (-1.24%)

NVS

Novartis

$74.42

-1.13 (-1.50%)

NVO

Novo Nordisk

$33.53

-0.39 (-1.15%)

  • 07

    Mar

  • 07

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 29

    Mar

  • 01

    Apr

  • 26

    Jun

AZN AstraZeneca
$29.51

-0.11 (-0.37%)

03/07/17
LEHM
03/07/17
UPGRADE
LEHM
Overweight
AstraZeneca reinstated with an Overweight from Equal Weight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated AstraZeneca with an Overweight rating. The rating is upgraded from Barclays' previous rating of Equal Weight. The analyst sees catalysts and growth inflecting in 2018. He has a price target of GBP 60 for Astra shares.
02/17/17
WBLR
02/17/17
NO CHANGE
WBLR
Outperform
William Blair estimates $102/share buyout value for SAGE
After SAGE Therapeutics (SAGE) CEO Jeff Jonas noted during an interview yesterday that his company has received takeover interest, William Blair analyst Tim Lugo made some estimates on what SAGE could garner in a takeout scenario. An acquisition is unlikely before the Phase III studies set to report out through midyear as well as several other proof-of-concept studies, Lugo cautions. He believes, however, that the company's "strong pipeline of central nervous system targeting therapies" would be complementary to a number of larger companies, including Allergan (AGN), AstraZeneca (AZN) and potentially Biogen (BIIB). When using comparable acquisitions of companies in the pre-commercial phase with a median premium of 55% to the prior close and a 2.8 times enterprise value to his peak sales estimate of $1.5B, Lugo arrives at potential takeover value for SAGE of $102 per share, or a $4.2B enterprise value. Using a sum-of-the-parts analysis, the analyst arrives at a fair-value estimate between $95 and $100 per share. SAGE in early trading is down $2.36 to $60.39. Lugo has an Outperform rating on the stock.
01/30/17
SBSH
01/30/17
NO CHANGE
Target $151
SBSH
Buy
TESARO could be worth up to $238/share in a takeover, says Citi
Citi analyst Robyn Karnauskas estimates that TESARO (TSRO) could be valued at $208-$238 per share in a deal to be acquired. The stock closed Friday up 49c to $153.85. Multiple catalysts in TESARO's immune-oncology program throughout 2017 could cause investors to gain confidence and assign value to the program, Karnauskas tells investors in a research note. She keeps a Buy rating on the shares with a $151 price target. The analyst says she's been getting questions around the competitive landscape in the PARP space and potential M&A valuations ahead of the SOLO-2 data from AstraZeneca (AZN) expected in Q1.
02/21/17
BREN
02/21/17
NO CHANGE
BREN
AstraZeneca 'turnaround..approaching,' says Berenberg
Bernberg analyst Alistair Campbell lowered his 2017 EPs estimate for AstraZeneca to nearly 50% below consensus levels, citing faster erosion of legacy drugs. However, the analyst expects the company to make deals that will raise its EPS above this level, and he says that the company will report a great deal of news in 2017. Moreover, he says that data on the company's Lynparza drug for breast cancer was positive, giving it a "good start," while the company's pipeline and new drugs should enable it to resume growing within the next two years. Campbell says that the company's "turnaround is approaching," and he keeps a Buy rating on the shares.
RHHBY Roche
$32.31

-0.11 (-0.34%)

03/02/17
RBCM
03/02/17
NO CHANGE
RBCM
Puma Biotechnology price target lowered to $17 from $57 at RBC Capital
RBC Capital analyst Simos Simeonidis cut the price target on Puma (PBYI) twice in one day, first to $48 from $57 and then to $17 from $48. The analyst says that, in the wake of positive data on Roche's (RHHBY) breast cancer treatment,Perjetab, reported this morning, "the commercial opportunity for (Puma's) neratinib in the extended adjuvant setting should be considered as (most likely) eliminated." The analyst adds that GI concerns about Puma's drug increase the likelihood of it not being used in the extended adjuvant setting. Simeonidis expects Puma to attempt to market neratinib in the EU and the rest of the world on its own. He keeps a Sector Perform rating on the name.
03/02/17
JPMS
03/02/17
NO CHANGE
JPMS
Overweight
Puma best-case off table with positive Roche study, says JPMorgan
JPMorgan analyst Cory Kasimov says that while Roche's (RHHBY) positive Aphinity trial results take the near-term best-case scenario off the table for Puma Biotechnology (PBYI), the ultimate impact on Puma "remains to be seen." The future of Puma's neratinib in the adjuvant breast cancer setting largely rests on the nuances of the Roche data, namely the magnitude of benefit, the subgroups that drive the benefit and details of the safety profile, Kasimov tells investors in a research note while pointing out that Roche's press release is light on details. The analyst initially expected that positive Aphinity results would take a third of the value out of Puma shares. Kasimov adds, however, that investor feedback this morning suggests the selloff could provide an opportunity ahead of Aphinity study details at ASCO and pending neratinib data points in first half of 2017. Puma shares are down 25%, or $9.50, to $29 in pre-market trading. Roche shares are up 6% to $32.30.
03/02/17
SBSH
03/02/17
NO CHANGE
Target $88
SBSH
Buy
Citi sees 'significant upside' in Puma shares, says buy the selloff
Citi analyst Yigal Nochomovitz recommends using this morning's selloff in shares of Puma Biotechnology (PBYI) as a buying opportunity. The stock in pre-market trading is down 24%, or $9.25, to $28.80. The Roche (RHHBY) press release does not provide any numbers on magnitude of benefit or any details on benefit in subgroups, Nochomovitz tells investors in a research note after the Aphinity trial met its endpoint. The analyst adds that today's press release does not definitively state Roche will be filing on the data, rather noting that, "These data will be discussed with health authorities across the world, including the US FDA with the hope to convert the current US accelerated approval to a full approval." It is hard to ignore the word choice of "hope" as opposed to "expectation," Nochomovitz contends. He continues to expect Puma's neratinib to receive FDA approval by the action date in July for extended adjuvant. The analyst said he sees "significant upside" in the shares. Further, Nochomovitz thinks Puma's breast cancer opportunities outside of adjuvant can justify the current valuation without any extended adjuvant revenue. He has a Buy rating on Puma with an $88 price target.
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Overweight
Roche reinstated with an Overweight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated Roche with an Overweight rating and CHF 310 price target.
SHPG Shire
$184.48

-1.82 (-0.98%)

03/07/17
LEHM
03/07/17
INITIATION
LEHM
Overweight
Shire reinstated with an Overweight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated Shire with an Overweight rating and GBP 65 price target. The rating is unchanged from last year.
01/19/17
01/19/17
NO CHANGE

Shire's application for ADHD disorder candidate acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder. The FDA is expected to provide a decision on or around June 20. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. Launch is planned for the second half of 2017.
12/06/16
UBSW
12/06/16
DOWNGRADE
UBSW
Neutral
Shire downgraded to Neutral from Buy at UBS
12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GSK GlaxoSmithKline
$41.55

-0.27 (-0.65%)

03/07/17
LEHM
03/07/17
DOWNGRADE
LEHM
Equal Weight
GlaxoSmithKline reinstated with an Equal Weight from Overweight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated GlaxoSmithKline with an Equal Weight rating. The rating is a downgrade from Barclays' previous rating of Overweight. The analyst sees a lack of pipeline catalysts and has a GBP 15.50 price target for the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
02/14/17
RBCM
02/14/17
NO CHANGE
RBCM
Gilead data better than expected, says RBC Capital
RBC Capital analyst Michael Yee says that data on Gilead's (GILD) HIV treatment, bictegravir, shows that the drug was more effective than GlaxoSmithKline's (GSK) dolutegravir in treatment-naive HIV patients. The analyst thinks that the data indicates that Gilead's HIV franchise should be valued at $50+ per share, although he warns that data on a GlaxoSmithKline treatment due to next year could pose a threat to Gilead. He keeps an Outperform rating on Gilead.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
SNY Sanofi
$43.16

-0.54 (-1.24%)

03/07/17
LEHM
03/07/17
INITIATION
LEHM
Underweight
Sanofi initiated with an Underweight at Barclays
Barclays analyst Emmanuel Papadakis initiated Sanofi with an Underweight rating and EUR 70 price target.
02/09/17
02/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying the company's first quarter results prove its turnaround is "real and likely to continue." The strategic plan put in place by CEO Bakish makes sense, Ryvicker tells investors in a research note. The analyst raised his price target range for the shares to $48-$50 from $38-$40. 2. Micron (MU) upgraded to Buy from Underperform at BofA/Merrill. 3. Sanofi (SNY) upgraded to Buy from Neutral at Natixis. 4. Hawaiian Holdings (HA) upgraded to Outperform from Peer Perform at Wolfe Research. 5. Baker Hughes (BHI) upgraded to Positive from Neutral at Susquehanna with analyst Charles Minervino citing the selloff in shares and its upside opportunity associated with a US spending upcycle, synergies from its joint-venture with General Electric (GE), and the growth opportunities that could develop from a partnership with a diversified global oilfield services company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
NTXS
02/09/17
UPGRADE
NTXS
Buy
Sanofi upgraded to Buy from Neutral at Natixis
01/26/17
RHCO
01/26/17
NO CHANGE
RHCO
Buy
SunTrust reiterates $165 bull case target for TESARO
The PARP inhibitor space has garnered more investor attention following TESARO's (TSRO) "robust" data in ovarian cancer with niraparib and approval of Clovis Oncology's (CLVS) PARP inhibitor in December 2016, SunTrust analyst Peter Lawson tells investors in a midday research note. With takeover speculation surrounding TESARO today, the analyst notes that his bull case analysis yields a price target of $165. For Clovis, his bill case analysis yields a $64 price target. He sees "plenty of catalyst" for both and keeps Buy ratings on the shares. Piper Jaffray this morning upgraded Clovis to Overweight. In midday trading, TESARO is up $15.33 to $155.33 while Clovis is up $3.32 to $61.74. The website StreetInsider earlier today reported that a "person claiming to have knowledge of the matter" said Sanofi (SNY) is examining an acquisition of TESARO.
NVS Novartis
$74.42

-1.13 (-1.50%)

03/07/17
EXAN
03/07/17
DOWNGRADE
EXAN
Underperform
Novartis downgraded to Underperform from Neutral at Exane BNP Paribas
03/07/17
03/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Novartis (NVS) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Kroger (KR) downgraded to Neutral from Buy at Northcoast with analyst Chuck Cerankosky saying he sees little chance of earnings acceleration and or surprise over the next six months and is forecasting flat to slightly down operating earnings for fiscal 2017. 3. Casey's General Stores (CASY) downgraded to Sector Perform from Outperform at RBC Capital with analyst Irene Nattelciting the company's tepid third quarter report. 4. Diebold (DBD) downgraded to In-Line from Outperform at Imperial Capital with analyst Jeff Kessler saying the company's next four to six quarters are "likely to be characterized by a large and complex integration project for management." The analyst keeps a $30 price target for the shares. 5. Frontier Communications (FTR) downgraded to Neutral from Buy at BofA/Merrill with analyst David Barden saying the topline revenue has declined at a surprising rate, creating risk to the dividend. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
SOCG
03/07/17
UPGRADE
SOCG
Buy
Novartis upgraded to Buy from Hold at Societe Generale
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Underweight
Novartis reinstated with an Underweight at Barclays
Barclays analyst Emmanuel Papadakis reinstated Novo Nordisk with an Underweight rating.
NVO Novo Nordisk
$33.53

-0.39 (-1.15%)

02/02/17
DBAB
02/02/17
NO CHANGE
DBAB
Novo Nordisk added to short-term buy list at Deutsche Bank
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Underweight
Novo Nordisk reinstated with an Underweight at Barclays
Barclays analyst Emmanuel Papadakis reinstated Novo Nordisk with an Underweight rating and DKK 210 price target. The analyst believes the valuation premium to the group is unwarranted and feels the company's 2017 guidance "does not look cautious."
01/04/17
JPMS
01/04/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novo Nordisk yesterday to Underweight saying consensus expectations are not reflecting the potential for further pricing pressure in the U.S. The analyst has a DKR 225 price target for the shares.
01/03/17
JPMS
01/03/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan

TODAY'S FREE FLY STORIES

CNX

Consol

$16.50

0.465 (2.90%)

14:30
11/17/17
11/17
14:30
11/17/17
14:30
Options
Far upside call buyer in CNX »

Far upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

, AMGN

Amgen

$170.77

1.39 (0.82%)

14:29
11/17/17
11/17
14:29
11/17/17
14:29
Periodicals
Xenon higher as CNBC's Tirrell reports on nonaddictive pain medicines »

Six drug companies are…

XENE

Xenon Pharmaceuticals

AMGN

Amgen

$170.77

1.39 (0.82%)

RHHBY

Roche

$28.90

0.165 (0.57%)

BIIB

Biogen

$313.98

3.7 (1.19%)

RGEN

Repligen

$33.73

1.12 (3.43%)

VRTX

Vertex

$147.94

-0.72 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 23

    Dec

  • 03

    Feb

  • 23

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

RIO

Rio Tinto

$47.70

0.065 (0.14%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Periodicals
Rio Tinto working with advisers on bid for stake in SQM, Bloomberg says »

Rio Tinto has lined up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$23.69

-0.92 (-3.74%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Options
Viacom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
11/17/17
11/17
14:25
11/17/17
14:25
General news
Action Economics Survey results »

Action Economics Survey…

TWX

Time Warner

$88.79

0.7799 (0.89%)

, DIS

Disney

$103.63

0.03 (0.03%)

14:23
11/17/17
11/17
14:23
11/17/17
14:23
Periodicals
'Justice League' grosses roughly $16M in opening day in China, Forbes says »

Warner Bros. (TWX) latest…

TWX

Time Warner

$88.79

0.7799 (0.89%)

DIS

Disney

$103.63

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/17/17
11/17
14:17
11/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/17/17
11/17
14:16
11/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.77

-0.12 (-0.81%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Conference/Events
Pan American Silver investor and analyst day »

Investor and Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TJX

TJX

$70.99

1.93 (2.79%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Options
Notable options activity in TJX as shares see strength »

Notable options activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFSW

PFSweb

$6.80

0.21 (3.19%)

13:59
11/17/17
11/17
13:59
11/17/17
13:59
Hot Stocks
PFSweb rallies after Ancora discloses activist stake »

Ancora Advisors earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$103.86

-0.95 (-0.91%)

13:52
11/17/17
11/17
13:52
11/17/17
13:52
Recommendations
RH analyst commentary  »

RH price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$38.49

1.76 (4.79%)

13:45
11/17/17
11/17
13:45
11/17/17
13:45
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$51.40

0.015 (0.03%)

13:36
11/17/17
11/17
13:36
11/17/17
13:36
Syndicate
Breaking Syndicate news story on PSEG »

PSEG files $129.1M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$89.05

-0.64 (-0.71%)

13:33
11/17/17
11/17
13:33
11/17/17
13:33
Hot Stocks
Indiana American Water acquires Georgetown Water System for about $6.4M »

Indiana American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$16.86

0.36 (2.18%)

13:30
11/17/17
11/17
13:30
11/17/17
13:30
Options
Cott Corp call buying continues »

Cott Corp call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
11/17/17
11/17
13:30
11/17/17
13:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

CC

Chemours

$52.23

0.705 (1.37%)

13:27
11/17/17
11/17
13:27
11/17/17
13:27
Periodicals
Chemours tells Bloomberg N.C. permit revocation 'unwarranted' »

The comment was issued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

13:25
11/17/17
11/17
13:25
11/17/17
13:25
General news
An exodus from U.S. high yield debt this week »

An exodus from U.S. high…

STBZ

State Bank Financial

$28.69

0.21 (0.74%)

13:25
11/17/17
11/17
13:25
11/17/17
13:25
Conference/Events
State Bank Financial participates in a conference call with SunTrust »

Suntrust Bank Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

HIBB

Hibbett Sports

$14.85

0.8 (5.69%)

13:24
11/17/17
11/17
13:24
11/17/17
13:24
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

FL

Foot Locker

$40.18

8.33 (26.15%)

13:23
11/17/17
11/17
13:23
11/17/17
13:23
Recommendations
Foot Locker analyst commentary  »

Foot Locker quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

MS

Morgan Stanley

$48.67

0.065 (0.13%)

13:20
11/17/17
11/17
13:20
11/17/17
13:20
Options
Morgan Stanley calls lead puts 9:1 »

Morgan Stanley calls lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
11/17/17
11/17
13:17
11/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/17/17
11/17
13:16
11/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.